Analyst Price Target is $36.00
▲ +771.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 771.67% upside from the last price of $4.13.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Inventiva. This rating has held steady since October 2022, when it changed from a Buy consensus rating.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.